France’s Therachon completes $60 million mezzanine financing

08/13/2018 8:23:00 AM (GMT)

French clinical-stage biotechnology company Therachon announced it has completed a $60 million mezzanine financing.

The round was led by Novo Holdings and joined by new investors Cowen Healthcare Investments, Pfizer Ventures, and funds managed by Tekla Capital Management LLC.

Existing investors Versant Ventures, OrbiMed, Bpifrance and Inserm Transfert Initiative also participated.

Therachon plans to use the proceeds to advance the company’s lead pipeline candidate TA-46, a novel protein therapeutic for achondroplasia.

Therachon

All success stories are prepared by Investsize editors which is selecting elite and remarkable information from press releases and anonymous news sources.There is no charge applied for any success stories which is published . Those published success stories are not investment advices and doesnt offer recommendations Alternate Text